title: Optimized treatment with RF thermotherapy and immunotherapy combined with CyberKnife for advanced high-risk tumors: A clinical trial report.
abstract: This study was conducted to evaluate the application value of optimized treatment with radiofrequency (RF) thermotherapy and immunotherapy combined with CyberKnife for advanced high-risk tumors. The database of 1,013 patients with 2,136 tumor lesions and 1,237 target areas who underwent treatment with CyberKnife between November, 2010 and November, 2012, was retrospectively reviewed. We randomly assigned 505 eligible patients (observation group) to RF thermotherapy and adoptive immunotherapy with cytokine-induced killer cells and the remaining 508 patients (control group) to no adjuvant treatment. The patients in the two groups were recorded on efficacy assessment according to imageological examination, World Health Organization criteria, Karnofsky performance status, or radioimmunoassay (RIA) detection. The effective rate of the observation group was 75.05%, whereas that of the control group was 58.06% (P<0.05). The results revealed that CyberKnife combined with hyperthermia and biological therapy are highly effective in improving the local tumor control rate. Further analysis of the Karnofsky score and RIA detection confirmed that this type of combination therapy significantly improved the quality of life. The optimized treatment of RF thermotherapy and immunotherapy combined with CyberKnife may act synergistically in eliminating tumor cells, confirming the efficacy of this type of treatment for patients with advanced malignant tumors.
authors.affiliation: Binzhou Medical College, People's Liberation Army 107th Hospital, Yantai, Shandong 264003, P.R. China.
authors.forename: Zhigao
authors.initials: Z
authors.lastname: Jiang
authors.affiliation: Department of Radiotherapy, 307 Hospital Affiliated to the Military Academy of Medical Sciences, Beijing 100071, P.R. China.
authors.forename: Qinwen
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Center for Tumor Treatment, People's Liberation Army 107th Hospital, Yantai, Shandong 264003, P.R. China.
authors.forename: Guiqing
authors.initials: G
authors.lastname: Yang
authors.affiliation: Center for Tumor Treatment, People's Liberation Army 107th Hospital, Yantai, Shandong 264003, P.R. China.
authors.forename: Xiaoxu
authors.initials: X
authors.lastname: Liu
authors.affiliation: Center for Tumor Treatment, People's Liberation Army 107th Hospital, Yantai, Shandong 264003, P.R. China.
authors.forename: Dongning
authors.initials: D
authors.lastname: Sun
authors.affiliation: Binzhou Medical College, People's Liberation Army 107th Hospital, Yantai, Shandong 264003, P.R. China.
authors.forename: Shanshan
authors.initials: S
authors.lastname: Wang
authors.affiliation: Binzhou Medical College, People's Liberation Army 107th Hospital, Yantai, Shandong 264003, P.R. China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Li
authors.affiliation: Binzhou Medical College, People's Liberation Army 107th Hospital, Yantai, Shandong 264003, P.R. China ; Center for Tumor Treatment, People's Liberation Army 107th Hospital, Yantai, Shandong 264003, P.R. China.
authors.forename: Yishan
authors.initials: Y
authors.lastname: Wang
keywords: CyberKnife; advanced high-risk tumor; hyperthermia; immunotherapy; optimized treatment